Ondine Biomedical Share Discussion Threads

[purple11] 03/5/2024 07:16

Discussions are underway with HCA Healthcare's investment arm, Health Insight Capital, for its funding support of the key Phase 3 clinical trial. The Company is confident in its ability to secure longer-term financing to execute its growth opportunities. The Company has received an indication of further support from its founder, CEO and substantial shareholder, Carolyn Cross, to provide additional near-term funding to extend the Company's runway should that be required prior to arranging funding for the Phase 3 clinical trial and working capital.

[purple11] 03/5/2024 07:13

Carolyn Cross, CEO of Ondine, said:

"We are pleased to have the support of existing and new investors through this fundraising which meets our near-term working capital needs and assists our rapid commercial growth rate. This funding will take us forward commercially and further our discussions with industry partners on our clinical, financial, and global distribution objectives. We believe that our product, Steriwave, is very well positioned to help hospitals meet their infection control objectives, reduce their antibiotic usage and combat AMR in what is expected to be a multibillion-dollar market. Our commercial efforts are benefitting from the growing support for pre-surgical nasal decolonisation by leading organisations, as well as our real-world clinical successes in Canadian hospitals and adoption in other approved territories.



While we are currently focused on nasal decolonisation to prevent healthcare-associated infections, Steriwave is just the first of seven major market opportunities for our platform technology. In due course, pipeline products targeting the treatment of burns, wounds, chronic sinusitis, ventilator-associated pneumonia, and fungal infections will leverage our regulatory filings and the clinical successes related to our nasal decolonisation product."

[purple11] 03/5/2024 07:10

in today @6p

[premium beeks] 03/5/2024 07:06

Bought this morning

[purple11] 01/5/2024 12:39

not a very nice fellow is he?

how many times has he exited on his ramps leaving others to hold the baby?

nasty bit of work and a terrible stock picker.


READER BEWARE

[z1co] 01/5/2024 11:10

Read the thread i sold out at a profit and waiting to buy again.

Now go f#ck yourself.

WOW the thicko is a bellend

[purple11] 01/5/2024 10:44

ZICO THE CLOWN strikes again

halved since his buy in tip

it really is pot luck with this guy.His losers seem to far outweigh his odd winner

READER BEWARE

[banshee] 26/4/2024 14:42

OND does in fact face competion, e.g Destiny's XF-73 is equaly effective, also immune to the issue of resistance, and doesn't require a machine to activate it. Still, if I waa surgeon I might prefer OND's approach just because you can be 100% sure of compliance, though as a patient I would probably prefer XF-73.

When it comes to outpatient treatments for the prevention or treatment of infected wounds/ulcers etc which both companies are targetting in the more distant future, Destiny's products would appear to address a much larger market because, they can be applied outside a clinical setting, e.g at home, horses for courses.

[jailbird] 26/4/2024 10:23

"You should know that I have spent much of last year on my back ith a femur in shards screwed back together waiting for the bone to regrow. How could you know much sbout preaching from time spent behind bars?"

Now how would I know that?

I left you at CPX with your tail between your legs

Wish u a full recovery, health is wealth

[scrutable] 26/4/2024 10:08

apologies to others for duplex post

[scrutable] 26/4/2024 10:07

jailbird
You should know that I have spent much of last year on my back with a femur in shards screwed back together waiting for the bone to regrow. How could you know much sbout preaching from time spent behind bars?

The Bishop from the cathedral opposite my bedroom wundow in Exeter would never offer you his pulpit. It must be obvious to you, even though you are probably no longer in Clink why I am excited by photo disinfecton.

[nigoil] 26/4/2024 06:05

How are your 2.3p PPP shares doing purple11?...... LOL

Simples!....... :-)

[jailbird] 25/4/2024 21:04

ScrutableI have already embarrassed you about your CPX holding It is not cheap on fundamentals plus dilution on its way No doubt there is potential here but small emerging companies always have potential , it is whether the BoD have the expertise to deliver it to reach a wider commercialisation model There is hope here for sure , so if you are buying around here , you may be ok longer term .You have joined the discussion late so do not start preaching

[scrutable] 25/4/2024 20:28

MRSA bacteria are frightening. It is more and more difficult to find biocidal sprays which are effective in supressing them after surgery and recovery from heavy surgery is more and more compromised.
It may be an exaggeration to assert that this photo disinfection comes almost "in the nick of time" but not by very much. It offers a jump step in surgery. One without peer or competition.
Those who measure the economy in numbers will have noticed that the first flush of orders are seeded widely across the world and re-orders will ,I am certain, be exponential rather than turgidly linear. The market expansion coefficient just needs an order by a leading health institution inJapan, better still in Singapore and Hong Kong as well, which wil lead quickly into China. Then. Ondine ll be well away to the races. The last fly in the ointment is the 19th century approach to medical innovation at the FDA who I believe insist that any advance be first proven to be trouble free on animals and is incompatible with the speed of technology across the USA.

Ondine looks surprisingly cheap ahead of so much potential.

[purple11] 25/4/2024 09:21

they need to finalize funding promptly and put a floor under the price.

i will reveiw it once this has been done.atb

[molatovkid] 24/4/2024 06:36

Jailbird, you summarised my feelings 100%....no holding yet and only the financing putting me off. Definitely going places though

[bamboo2] 24/4/2024 06:27

Very crudely calculated, in 2023 16 hospitals produced $75,000 turnover each.

Like the partnership proposal.

[bamboo2] 24/4/2024 06:22

Corporate and Trading Update

Significant revenue growth and commercial momentum

Ondine Biomedical (LON: OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans.

Commercial

In 2023, revenues nearly doubled to $1.2 million ($0.6 million in 2022), driven by significant growth in the number of hospitals deploying Steriwave®. Ondine ended the year with 16 hospital deployments, up from six at the prior year end. This momentum has continued with eight additional hospital deployments in Q1 2024, bringing the total to 24 hospitals, 50% up from the previous year-end and four times the number at the beginning of 2023.

During the last quarter, several hospitals announced expansions to include other surgical indications. The Company is also benefitting from significantly reduced sales cycle times, lower new client acquisition costs and improved margins resulting from lower cost of goods and higher product pricing. Retention of hospital accounts added to date is at 100%.

Of the eight new hospital placements in the first quarter of 2024, five of these were located internationally:

· In the UK, strategic inroads were made into the NHS in England with the accelerated adoption by two hospitals in the Mid Yorkshire NHS Teaching Trust (the "Trust") for orthopedic surgeries as a result of a strong early pilot data in one of them, and high levels of enthusiasm for the new technology by both healthcare professionals and patients. The Trust created a 12-month budget for the use of Steriwave for patients undergoing hip and knee surgery. Ondine is now partnering with the Trust and Health Innovation Yorkshire and Humber to conduct a health economic analysis to further support Steriwave adoption across the NHS. In the private sector, HCA Healthcare UK has approved Steriwave for use in its UK-based private hospitals, at the discretion of the clinician. HCA UK, a leading private healthcare provider in the UK with 30 facilities, is a subsidiary of HCA Healthcare (USA).

· In Spain, the first three hospitals are now implementing Steriwave, including the prestigious Hospital Universitario La Paz (HULP). HULP is a large tertiary hospital in Madrid with 1,308 beds. The Hospital Universitario La Paz is recognized as a centre of reference and health excellence and is considered one of the top three public hospitals with the best reputation in Spain.

· In Australia, Ondine has achieved its first hospital deployment in Australia at Mater Hospital, North Sydney, a 233-bed private hospital in New South Wales. The hospital is part of the St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services. This follows the recent Australian Spine Society Conference held from 5-7 April 2024, at which Dr. John Street, Co-Medical Director of the Complex Spine Program at Vancouver General Hospital, presented his research study findings on Steriwave as keynote speaker.

Distribution Partnership(s) to accelerate growth: As a result of Ondine's positive clinical data, growing sales momentum and recent commercial success, the Company has been approached by several multinational companies in the hospital supply, wound care, and infection control industries. The Company is currently in a process of progressing discussions on distribution collaborations with potential partners. While these discussions have been constructive, there is no certainty that a distribution agreement will materialize from any of these discussions. Management believes that distribution partnerships have the potential to generate earlier income for Ondine in the form of time-based territorial license payments and to accelerate sales and income generation for the Company through faster market penetration and greater geographical reach. The Company's 2023 investments in manufacturing capacity upgrades combined with a significant COGS reduction program support larger-scale rollout and increased gross margins required by any potential partners. The latest generation light diffuser is reducing the cost of goods for our Steriwave testing kits by 46 per cent.

Expansion into Intensive Care Units (ICU): Ondine is accelerating its plans to enter the ICU market to take advantage of interest by hospitals to replace the commonly used antibiotic mupirocin. Mupirocin, the topically applied antibiotic used in the nose over 5 days, requires lengthy administration times and generates antibiotic resistance. Having established a solid safety and efficacy profile in over 150,000 patients in pre-surgical and industrial settings, the Company estimates that the ICU application represents an opportunity to expand the total addressable market for Steriwave significantly. As ICUs have the highest hospital rates of infection and mortality, they represent an opportunity to accelerate new hospital adoption at a point of major unmet need both in terms of improving patient outcomes and reducing cost of care and length of stay. Further announcements will be made in due course.

US Phase 3 Clinical Trial Plans

Following a Type C meeting with the US Food & Drug Administration ("FDA") last September, the design and budget for the clinical trial program has been finalized in close collaboration with HCA Healthcare ("HCA"), Ondine's US clinical trial partner. The trial will run at 14 HCA hospital sites with a circa 5,000-patient group-randomized crossover study, comparing Ondine's nasal photodisinfection added to standard-of-care infection prevention practices versus standard-of-care alone. The Company is targeting to commence the trial in the third quarter of this year. Data from the trial will inform the Company's planned FDA submission and approval would facilitate adoption of Steriwave in the US.

Funding Position and Support

The Company has received indications of support from its founder CEO and substantial shareholder, Carolyn Cross, and from other existing shareholders, to provide near-term funding to extend the Company's runway. Discussions are currently underway with HCA's investment arm, Health Insight Capital, for its funding support of the key Phase 3 clinical trial. The Company is confident in its ability to secure longer-term financing to execute on the growth opportunities described above. Further announcements will be made in due course.

[jailbird] 24/4/2024 06:15

A comprehensive update They have a great tech here, they have something great here .now to find a way to turn this to multi million revenues . It is a challenge for them and need partners on board to expand the reach.Cash is the issue here and as potential investors that is what we think about How can raise this without impacting share price via dilution Also I bet their competitors will do what they can to prevent losing market share But Really they should looking to buy this company

[marvelman] 22/4/2024 10:50

Totally agree Bamboo.

[bamboo2] 22/4/2024 07:33

With all these RNSNON, it seems likely to me that the company is collecting a huge dossier of empirical evidence that will likely obviate the need for an extensive trial in the US. Benefits of a more limited US trial would be reduced costs and earlier acceptance.